These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11918622)

  • 41. Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH).
    McPherson R; Angus C; Murray P; Genest J;
    Am Heart J; 2001 Jun; 141(6):949-56. PubMed ID: 11376309
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
    Wolffenbuttel BH; Franken AA; Vincent HH;
    J Intern Med; 2005 Jun; 257(6):531-9. PubMed ID: 15910557
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.
    Bone HG; Kiel DP; Lindsay RS; Lewiecki EM; Bolognese MA; Leary ET; Lowe W; McClung MR
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4671-7. PubMed ID: 17726081
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
    Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
    Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.
    Goldberg RB; Guyton JR; Mazzone T; Weinstock RS; Polis A; Edwards P; Tomassini JE; Tershakovec AM
    Mayo Clin Proc; 2006 Dec; 81(12):1579-88. PubMed ID: 17165637
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
    Gumprecht J; Gosho M; Budinski D; Hounslow N
    Diabetes Obes Metab; 2011 Nov; 13(11):1047-55. PubMed ID: 21812889
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE).
    Deedwania PC;
    Am Heart J; 2004 Dec; 148(6):1053-9. PubMed ID: 15632893
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
    Neil HA; DeMicco DA; Luo D; Betteridge DJ; Colhoun HM; Durrington PN; Livingstone SJ; Fuller JH; Hitman GA;
    Diabetes Care; 2006 Nov; 29(11):2378-84. PubMed ID: 17065671
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
    Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT
    J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of atorvastatin on serum lipoproteins in acromegaly.
    Mishra M; Durrington P; Mackness M; Siddals KW; Kaushal K; Davies R; Gibson M; Ray DW
    Clin Endocrinol (Oxf); 2005 Jun; 62(6):650-5. PubMed ID: 15943824
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
    Knopp RH; d'Emden M; Smilde JG; Pocock SJ
    Diabetes Care; 2006 Jul; 29(7):1478-85. PubMed ID: 16801565
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin.
    Bybee KA; Lee JH; O'Keefe JH
    Curr Med Res Opin; 2008 Apr; 24(4):1217-29. PubMed ID: 18358084
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
    J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
    Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
    Drugs; 2004; 64 Suppl 2():43-60. PubMed ID: 15765890
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of atorvastatin on pancreatic Beta-cell function and insulin resistance in type 2 diabetes mellitus patients: a randomized pilot study.
    Goyal A; Singh S; Tandon N; Gupta N; Gupta YK
    Can J Diabetes; 2014 Dec; 38(6):466-72. PubMed ID: 24933106
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia.
    Marais AD; Firth JC; Bateman ME; Byrnes P; Martens C; Mountney J
    Arterioscler Thromb Vasc Biol; 1997 Aug; 17(8):1527-31. PubMed ID: 9301631
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol.
    Wang KY; Ting CT
    Jpn Heart J; 2001 Nov; 42(6):725-38. PubMed ID: 11933922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.